WuXi Biologics (Cayman) Inc. (02269)

Equity Research Report　|　Industry: Biologics CRDMO　|　Report Date: September 13, 2026　|　As of the Hong Kong market close on September 11, 2026; the exact trading dates corresponding to the 52-week high and low have not been verified.

This report was automatically compiled by AI based on publicly available information and is for reference only. It does not constitute investment advice.

1. Executive Summary

WuXi Biologics (02269) reported revenue of RMB 11.787 billion in the first half of 2026, up 18.4% year on year (up 23.4% in US dollar terms). IFRS gross margin rose to 46.2%, while adjusted net profit attributable to owners was RMB 3.306 billion, up 38.4% year on year. This indicates that the progression of projects toward late-stage clinical development and commercial manufacturing, improved capacity utilization, and cost-reduction measures are driving the release of operating leverage. However, IFRS net profit attributable to owners increased by only 4.3% year on year, mainly due to unrealized foreign-exchange losses arising from the depreciation of the US dollar and the impact of the investment-gain base in the prior-year period. There is therefore a clear divergence between core operating improvement and reported profit growth.

The company’s end-to-end biologics CRDMO platform covers discovery, development, clinical manufacturing, and commercial manufacturing, and extends into the XDC business. Revenue in 2025 was RMB 21.790 billion, up 16.7% year on year, while gross margin recovered from 41.0% in 2024 to 46.0%. As of June 30, 2026, the total integrated project portfolio had increased to 1,064 projects, including 78 Phase III projects and 28 commercial manufacturing projects; 169 projects were added in the first half. Total backlog at the end of 2025 was approximately US$23.0 billion, including a service backlog of approximately US$11.5 billion. Approximately US$4.5 billion is expected to be recognized over the next three years, providing some visibility for medium-term revenue conversion.

The company’s revenue is highly internationalized, with North America and Europe together contributing approximately 81.2% of 2025 revenue. The top five customers accounted for 26.1% of 2025 revenue and the top ten customers for 37.6%, both lower than in 2024, although the purchasing and quality-negotiation power of large pharmaceutical customers continues to constrain pricing. In working capital, net trade receivables at the end of 2025 were RMB 7.647 billion, equivalent to approximately 35.1% of full-year revenue. Overdue trade receivables were approximately RMB 2.561 billion, including approximately RMB 1.094 billion overdue for more than 90 days. Customer credit and project-settlement risks therefore require continued monitoring.

As of September 11, 2026, the share price closed at HK$46.64, implying a forward P/E of approximately 33x to 35x and a P/B ratio of approximately 3.6x to 3.8x. Market consensus forecasts revenue of approximately RMB 25.220 billion to RMB 36.587 billion and net profit of approximately RMB 5.567 billion to RMB 8.626 billion for 2026 to 2028, although earnings definitions and forecast ranges vary among institutions. Technically, the share price was below the MA5, MA10, and MA20 and close to the Bollinger lower band at approximately HK$46.3. HK$46.1 to HK$46.4 is the short-term support-monitoring zone, while HK$49.0 to HK$49.5 is the resistance-monitoring zone around the moving averages and Bollinger mid-band.

2. Company Overview

2.1 Basic Information

2.2 Principal Businesses and Product Positioning

• Research services: including antibody discovery, protein discovery, bispecific antibodies, multispecific antibodies, T-cell engagers, single B-cell technology, and machine-learning-assisted antibody discovery. At the end of 2025, the company had approximately 800 scientists, and the combined number of bispecific- and multispecific-antibody-related projects was 196.
• Development services: covering cell-line development, process development, analytical methods, formulation development, drug-quality studies, viral-clearance studies, process validation, and regulatory filing support. In 2025, the company supported customers in completing 156 IND filings, expanding annualized filing capacity to approximately 200 INDs and 20 BLAs/MAAs.
• Manufacturing services: including drug-substance manufacturing, drug-product manufacturing, fill-finish, and packaging for clinical and commercial stages. At the end of 2025, the company had 945 integrated projects, including 74 Phase III projects and 25 commercial manufacturing projects.
• XDC business: providing CRDMO services for ADCs and other bioconjugates, covering antibody intermediates, conjugated drug substances, and drug products. External sales revenue was approximately RMB 5.900 billion in 2025.
• By project stage, pre-IND service revenue was RMB 9.314 billion in 2025, accounting for 42.8% of total revenue; Phase I and Phase II service revenue was RMB 2.639 billion, accounting for 12.1%; Phase III services and commercial manufacturing revenue was RMB 9.461 billion, accounting for 43.4%; and other revenue was RMB 376 million, accounting for 1.7%.

2.3 Position in the Industry Value Chain and Cost-Profit Structure

WuXi Biologics operates in the relatively high-value-added middle segment of the global biopharmaceutical value chain, connecting early-stage biologics research, clinical development, commercial manufacturing, and certain XDC services. The company does not primarily sell proprietary drugs. Instead, it generates service revenue, milestone payments, and certain sales-based or royalty-related income through its technology platforms, project execution, regulatory-compliance capabilities, global capacity, and customer switching costs.

• The company’s principal purchased and consumed inputs include cell-culture media, feeds, and other bioprocess raw materials; single-use bioreactor bags, filters, tubing, and storage bags; chromatography resins, membranes, and purification consumables; laboratory reagents and analytical-testing consumables; filling, packaging, and container components; water, electricity, gas, cleanroom operations, and facility maintenance; outsourced testing services; as well as research and production staff costs and depreciation of production facilities and equipment.
• The annual report divides cost of sales into direct labor costs, raw-material costs, and manufacturing overhead. Manufacturing overhead mainly includes depreciation of production facilities and equipment, outsourced testing fees, utilities, and repair and maintenance costs. In 2025, direct labor costs, raw-material costs, and manufacturing overhead accounted for 16.8%, 18.4%, and 18.8% of revenue, respectively.
• Supplier concentration based on 2025 disclosures: the top five suppliers accounted for approximately 36% of total purchases, compared with 41% in 2024; the largest single supplier accounted for approximately 15%, compared with 17% in 2024. Concentration declined year on year, but the company does not have complete pricing power over single-use consumables, filtration consumables, specialty resins, laboratory equipment, and certain high-end bioprocess materials.
• Some upstream suppliers may possess bargaining power based on delivery capabilities, validation cycles, and quality-certification requirements. This is an analytical assessment based on purchasing concentration and the characteristics of the biopharmaceutical supply chain, rather than a direct statement in the company’s annual report.
• Downstream customers include multinational pharmaceutical companies, large biotechnology companies, innovative biotechnology start-ups, and pharmaceutical companies that possess drug candidates but lack internal manufacturing capabilities and require clinical samples, commercial manufacturing, or dual sourcing globally. The company has established partnerships with the world’s 20 largest pharmaceutical companies.
• The 2025 geographic revenue distribution was: North America RMB 12.654 billion, or 58.1%; Europe RMB 5.042 billion, or 23.1%; mainland China RMB 2.680 billion, or 12.3%; and other regions RMB 1.415 billion, or 6.5%. North America and Europe together contributed approximately 81.2% of revenue, indicating a highly internationalized revenue base.
• Customer concentration as of December 31, 2025 was as follows: the top five customers contributed approximately RMB 5.688 billion, or 26.1% of total revenue, compared with 29.1% in 2024; the largest single customer accounted for 9.9%, compared with 11.1% in 2024; and the top ten customers contributed approximately RMB 8.184 billion, or 37.6%, compared with 41.7% in 2024. These data come from the company’s 2025 annual report, which provides 2024 comparisons; the latest annual report should prevail.
• Large pharmaceutical companies typically have strong purchasing, quality, and contract-negotiation capabilities, and WuXi Biologics does not possess complete downstream pricing power. Its bargaining power primarily derives from its integrated technology platforms, project-delivery speed, regulatory-compliance capabilities, global capacity, and high customer switching costs, rather than simple cost-plus pricing.
• CRDMO contracts typically adopt staged or milestone-based payments. Customer credit periods are generally 10 to 90 days, and some revenue is converted into trade receivables after development or production milestones specified in contracts are achieved. Staged collections and advance payments can reduce part of the capital tied up, but project delays, customer financing difficulties, or project failures may still create trade-receivable and contract-asset risks.
• As of December 31, 2025, net trade receivables were RMB 7.647 billion, equivalent to approximately 35.1% of 2025 revenue of RMB 21.790 billion. Based on the average receivables balance at the end of 2024 and 2025, estimated 2025 receivables turnover was approximately 110 days. This is a research estimate rather than an official metric directly disclosed in the annual report. At the end of 2025, non-overdue receivables were RMB 5.086 billion, receivables overdue by up to 90 days were RMB 1.467 billion, receivables overdue by 91 days to one year were RMB 771 million, and receivables overdue by more than one year were RMB 322 million. Total overdue receivables were approximately RMB 2.561 billion, including approximately RMB 1.094 billion overdue for more than 90 days. The company stated that, based on customer commitments and historical experience, some long-overdue balances are still expected to be recoverable, although these balances are unsecured. Overall, the company reduces some capital tied up through 10- to 90-day credit periods, advance payments, and staged payments, but the relatively high receivables ratio and overdue balance also indicate significant customer-credit and project-settlement risks.
• In terms of supplier concentration, the top five suppliers accounted for approximately 36% of total purchases in 2025 and the largest single supplier for approximately 15%. In terms of customer concentration, as of December 31, 2025, the top five customers accounted for 26.1% of revenue, the largest single customer for 9.9%, and the top ten customers for 37.6%. Both supplier and customer concentration declined from 2024, but the purchasing and quality-negotiation capabilities of large pharmaceutical companies continue to constrain the company. These concentration data are mainly from the company’s 2025 annual report, and the latest disclosure should prevail.

WuXi Biologics is a high-technology CRDMO platform in the middle of the global biopharmaceutical value chain, extending toward both research and commercialization. It is not a traditional low-value-added contract manufacturer. The company remains constrained by specialized consumables, facility depreciation, and contract negotiations with large pharmaceutical companies. Future margin expansion will depend primarily on utilization of new capacity, the share of commercial projects, growth in complex-molecule businesses such as bispecific antibodies and ADCs, ramp-up efficiency at global facilities, and digital cost reduction, rather than simply on lower raw-material prices.

3. Financial Data and Valuation Analysis

3.1 Recent Operating Performance

First-half 2026 data were from the unaudited interim results announced by the company on August 25, 2026. Basic EPS for the first half of 2026 was RMB 0.60, up 3.4% year on year; diluted EPS was RMB 0.58, up 5.5%. IFRS gross profit was RMB 5.448 billion, up 28.1%, with a gross margin of 46.2%, up 3.5 percentage points; adjusted gross margin was 48.4%, up 2.8 percentage points; adjusted EBITDA was approximately RMB 5.4 billion, up 24.9%, with an adjusted EBITDA margin of 45.6%; and free cash flow was approximately RMB 1.5 billion.

Revenue maintained relatively rapid growth in the first half of 2026, driven mainly by new IND projects, project progression into later clinical stages, and an increase in commercial manufacturing projects. Adjusted net profit attributable to owners increased by 38.4%, substantially above the 4.3% growth in IFRS net profit attributable to owners, mainly due to the impact of unrealized foreign-exchange losses caused by the depreciation of the US dollar and the investment-gain base in the prior-year period. Adjusted profit better reflects core operating trends, but should not completely replace the IFRS measure.

3.2 Earnings Forecasts

Etnet aggregated 16 broker reports as of early September 2026 and provided consensus forecasts for net profit and EPS; MarketScreener provided revenue forecasts. Different broker forecasts may use IFRS net profit, net profit attributable to owners, or adjusted net profit, and therefore cannot be directly compared one-for-one with the adjusted profit disclosed by the company. Revenue forecasts differ across pages, possibly due to differences in update dates, analyst samples, or consolidation scope, and do not represent official company guidance. In late August 2026, CICC raised its 2026 and 2027 adjusted net profit forecasts to RMB 6.665 billion and RMB 7.900 billion, respectively. Citi raised its 2026 to 2028 revenue forecasts by 2%, 3%, and 8%, respectively, and its EPS forecasts by 10%, 10%, and 17%, respectively.

3.3 Valuation and Institutional Ratings

At the September 11, 2026 close, the share price was HK$46.64 and turnover was approximately HK$1.327 billion. The Etnet/First Shanghai quote page showed a P/E ratio of approximately 33.04x. Etnet had earlier shown a P/E of approximately 35.9x and a P/B ratio of approximately 3.83x on August 31, 2026. Because of differences in data dates and earnings bases, these figures do not fully represent the real-time valuation on September 11. Based on Etnet’s 2026 consensus EPS of RMB 1.37 and an illustrative exchange rate of HK$1.13 per RMB, forecast EPS was approximately HK$1.55, implying a 2026 forward P/E of approximately 30.1x. As of June 30, 2026, the company’s net asset value per share was approximately RMB 11.602, or approximately HK$13.11 after conversion. Based on a share price of HK$46.64, the estimated P/B ratio was approximately 3.56x. Considering data from different pages, P/B is more appropriately understood as approximately 3.6x to 3.8x. As of June 30, 2026, approximately 4.145 billion shares had been issued. Based on the closing price, total market capitalization was approximately HK$193.3 billion, although different platforms may show approximately HK$197.0 billion to HK$210.0 billion. Etnet’s aggregation of 16 broker reports showed a consensus Buy rating and an average rating score of 2.06, comprising one Strong Buy, 13 Buys, two Holds, and no Sell ratings. Etnet listed 15 target prices, with a simple average of approximately HK$59.32 and a range of HK$35.80 to HK$67.80. Relative to the HK$46.64 closing price, the average target price implied potential upside of approximately 27.2%; CICC’s HK$60 target price implied potential upside of approximately 28.6%. Current valuation already reflects expectations for revenue recovery, margin improvement, and growth in complex-molecule businesses, and does not represent a traditionally low valuation. If revenue growth, overseas orders, or gross margin fall below expectations, the valuation could contract. If adjusted profit continues to grow by more than 20%, earnings growth may continue to absorb part of the valuation. The target prices represent broker research views, while valuation and earnings forecasts are also affected by US regulatory policies, foreign exchange, overseas capacity, project conversion, and differences in forecast definitions.

4. Recent News and Announcements

4.1 September Option Exercises Resulted in Share Issuances; at Least Approximately 8.3289 Million New Shares

As of September 13, 2026, WuXi Biologics’ principal announcements from early September through September 9 focused on its pre-IPO share option scheme and other option exercises. On September 2, 2026, the company disclosed its monthly return on movements in securities for the month ended August 31 and issued approximately 1.505 million ordinary shares upon the exercise of share options. It issued 2.4239 million ordinary shares on September 3, 3.2 million ordinary shares on September 4 at an issue price of HK$2.64 per share, involving approximately HK$8.45 million, and 1.2 million ordinary shares on September 9, also at an issue price of HK$2.64 per share. Based on currently cross-verifiable announcement data, at least approximately 8.3289 million new shares were issued in aggregate. These issuances resulted from the exercise of existing employee or management share options and did not constitute a new placing of shares to the market. Some announcement pages do not fully display the exercise price and other details relating to the 1.505 million shares. The relevant Hong Kong Stock Exchange monthly returns and next-day disclosure returns should prevail.

4.2 Option Exercises Caused Minor Dilution; Total Issued Shares Rose to Approximately 4.156 Billion

Following the issuance of 3.2 million shares on September 4, the number of issued shares rose from 4,149,729,787 to 4,152,929,787, with the new shares representing approximately 0.07711% of issued shares before the issuance. Following the issuance of 1.2 million shares on September 9, the new shares represented approximately 0.02888% of issued shares at that time, and total issued shares after the issuance rose to 4,155,933,877. According to the research summary, the dilution from option exercises was small relative to total share capital.

4.3 Existing Repurchased Shares Had Not Yet Been Cancelled; No New On-Market Buybacks Were Seen in September

On May 26, 2026, the company announced a proposed open-market share-repurchase program of up to HK$3.1 billion. Hong Kong Stock Exchange data show that the company repurchased an aggregate of 39,824,500 shares between May 27 and July 7, at prices ranging from HK$29.46 to HK$36.75 per share, for an aggregate amount of approximately HK$1.272 billion. At the time of the relevant September announcements, the repurchased shares were still intended for cancellation, but cancellation had not yet been completed. The announcements on September 2, 3, 4, 7, and 9 mainly comprised next-day disclosure returns under the “Other” category. Existing information does not show that the company resumed new on-market repurchases in September 2026. Recent changes in share capital therefore consisted of repurchased shares pending cancellation alongside new shares issued through option exercises.

4.4 No Major September Disclosure of Significant Shareholder Purchases, Sales, or Interests Changes Was Found

As of September 13, 2026, no major September disclosure was found concerning a sale, purchase, or change in interests by a major WuXi Biologics shareholder. Publicly disclosed changes in share capital in early September mainly arose from option exercises rather than trading by the controlling shareholder or major institutional shareholders. Stock Connect holdings data showed that, as of September 7, 2026, Stock Connect holdings in WuXi Biologics had increased by approximately 12.8 million shares from the previous period, with the market value of holdings increasing by approximately HK$621 million. This is market holdings data rather than a formal disclosure of interests by the company and cannot be directly equated with an increase by a single shareholder.

4.5 Short Selling Was Active in September, but It Cannot Be Directly Interpreted as Major-Shareholder Selling

On September 3, 2026, WuXi Biologics’ short-selling volume was approximately 7.0995 million shares and short-selling turnover was approximately HK$359 million, accounting for approximately 16.11% of the day’s turnover. On September 9, short-selling volume was approximately 3.777 million shares and short-selling turnover was approximately HK$186 million, accounting for approximately 17.48% of turnover. On September 11, short-selling volume was approximately 4.907 million shares and short-selling turnover was approximately HK$230 million, accounting for approximately 14.64% of turnover. Short-selling data reflect hedging or bearish activity at the trading level, but cannot be directly interpreted as selling by major shareholders.

4.6 First-Half 2026 Revenue and Adjusted Net Profit Attributable to Owners Increased

On August 25, 2026, the company disclosed interim results for the six months ended June 30, 2026. Revenue for the period was RMB 11.7872 billion, up 18.4% year on year; revenue in US dollar terms increased 23.4%. IFRS gross profit was RMB 5.4483 billion, up 28.1%, with an IFRS gross margin of 46.2% and an adjusted gross margin of 48.4%. IFRS net profit was RMB 2.9162 billion, up 5.8%; net profit attributable to owners was RMB 2.4398 billion, up 4.3%; and adjusted net profit attributable to owners was RMB 3.306 billion, up approximately 38.4%. The company stated that the difference between IFRS net profit and adjusted profit growth was mainly due to unrealized foreign-exchange losses caused by the depreciation of the US dollar and the investment-gain base in the prior-year period. The company did not declare an interim dividend for the six months ended June 30, 2026.

4.7 Total Integrated Projects Reached 1,064, Including 28 Commercial Manufacturing Projects

As of June 30, 2026, the company had 1,064 integrated projects, including 78 Phase III projects and 28 commercial manufacturing projects. It added 169 integrated projects in the first half of 2026, including 123 organically added projects and 46 projects from the acquisition of TopAlliance Biosciences by WuXi XDC. The 123 organically added projects increased 43% year on year.

4.8 Technology Licensing and Strategic Cooperation Agreement with Transcenta

On September 9, 2026, Transcenta Therapeutics, a subsidiary of Kangfang Biotech, and its subsidiaries announced that they had entered into a technology licensing and strategic cooperation agreement with WuXi Biologics. Transcenta will grant WuXi Biologics and its affiliates a non-exclusive technology license relating to the Highly Intensified Continuous Bioprocessing platform (HiCB) and ExcelPro cell-culture media, and will receive an upfront payment of RMB 10 million. Upon satisfaction of agreed conditions, Transcenta will also be eligible to receive milestone payments. This is a technology licensing and strategic cooperation arrangement, rather than a material acquisition disclosed by WuXi Biologics. Public information does not disclose the potential milestone amounts payable by WuXi Biologics, the number of cooperation projects, or the expected revenue contribution. Its short-term financial impact is therefore uncertain.

4.9 No Major Regulatory Penalties, Business Bans, or Material M&A Announcements Seen as of September 13

As of September 13, 2026, no September company announcement was found concerning regulatory penalties, listing status, business bans, or material compliance events involving WuXi Biologics. Recent public information mainly focused on interim results, technology platforms, commercial manufacturing, and international customer projects. The company’s interim-results announcement stated that it would continue advancing its global manufacturing network, quality system, and compliance standards. However, existing information does not indicate that risks relating to global regulation, geopolitics, data compliance, or supply-chain security have been completely eliminated.

5. Share-Price Trend and Technical Analysis

5.1 Price Overview

5.2 Technical Indicators

As of September 11, 2026, WuXi Biologics closed at HK$46.64, below the MA5, MA10, and MA20 of approximately HK$48.15, HK$48.82, and HK$49.21, respectively. The short-term moving-average structure was weak. The share price was also close to the Bollinger lower band at approximately HK$46.3, and the intraday low was HK$46.16, placing the stock near the lower end of its recent trading range. However, RSI was approximately 56.10 as of September 10 and had not entered the traditional oversold zone. Therefore, proximity to the lower band alone does not imply that a rebound is inevitable. The short-term focus is the contest between the HK$46.1 to HK$46.4 support zone and the HK$49.0 to HK$49.5 resistance zone. Trading volume and the short-selling share of turnover will affect confirmation of the breakout direction.

5.3 Short-Term Outlook (Next Week, Scenario Analysis for Reference Only)

⚠️ Risk warning: The following is a subjective scenario analysis based on closing data as of September 11, 2026. It does not constitute investment advice or a definitive forecast of future share prices.

① Key Technical Levels

② Scenarios for the Next Week (Subjective Weightings, Not Statistical Probabilities)

• Range-bound consolidation (relatively high subjective weighting, approximately six-tenths; a heuristic assessment based on current technical conditions and capital-flow proxy indicators, not a statistical probability): The reference price range is HK$46.2 to HK$49.5. The trigger would be the stock holding the HK$46.1 to HK$46.4 support zone but failing to break HK$49.0 to HK$49.5 decisively, while the healthcare sector and Hang Seng Index do not experience a clear one-way move and turnover remains around HK$1.0 billion to HK$1.5 billion. Technically, the share price may oscillate between the Bollinger lower band and mid-band. Short-term moving averages would remain weak, but no clear breakdown would yet have occurred.
• Weak downward move (medium subjective weighting; a heuristic assessment based on current technical conditions and capital-flow proxy indicators, not a statistical probability): The reference price range is HK$44.4 to HK$46.2. The trigger would be a sustained close below HK$46.1 to HK$46.3, accompanied by a clear increase in daily turnover to above approximately HK$1.8 billion, while the short-selling share of turnover remains high or the healthcare sector declines in tandem. Technically, a break below the Bollinger lower band and recent low could lead to a retracement toward the HK$44.4 to HK$45.0 strong-support zone. A break below HK$44.4 would further weaken the short-term structure.
• Rebound and strengthening (low to medium subjective weighting; a heuristic assessment based on current technical conditions and capital-flow proxy indicators, not a statistical probability): The reference price range is HK$49.5 to HK$51.4, with the area around HK$52 in focus in a strong scenario. The trigger would be the share price regaining and holding HK$49.0 to HK$49.5, daily turnover reaching approximately HK$1.8 billion or more and subsequently remaining high, while the healthcare sector strengthens in tandem and the short-selling share declines. Technically, only after recovering the MA20 and Bollinger mid-band would the short-term outlook have an opportunity to shift from weak to neutral. A further break above HK$50.5 to HK$51.4 would bring the upper-band area around HK$52 into focus.

③ Capital and Liquidity Background

As of September 11, 2026, based on turnover of approximately HK$1.327 billion and estimated market capitalization of approximately HK$193.8 billion calculated using the closing price, the daily turnover ratio was approximately 0.68%. Lixinger showed a turnover ratio of approximately 0.58% and turnover of approximately HK$1.157 billion as of September 10. Recent daily turnover ratios were generally around 0.6% to 0.7%, with normal daily turnover of approximately HK$1.0 billion to HK$1.5 billion and high-volume days reaching HK$1.8 billion to HK$2.5 billion or more. Trading volumes on August 26, August 25, August 20, August 31, September 3, and September 4 were approximately 88.95 million, 60.11 million, 70.13 million, 47.44 million, 44.02 million, and 41.65 million shares, respectively. The Investing.com page showed approximately 13.63 million shares on September 11, versus approximately 28.414 million shares according to Etnet, reflecting a significant methodological difference. Short-selling volume on September 11 was approximately 4.907 million shares, with short-selling turnover of approximately HK$230 million, representing approximately 14.637% of daily turnover. The short-selling shares of turnover from September 9 to 11 were approximately 17.483%, 18.124%, and 14.637%, respectively, indicating some short-term hedging and selling pressure, although the short-selling ratio is not equivalent to net capital outflow. Regarding shareholder information, Hong Kong Stock Exchange Disclosure of Interests data as of February 13, 2026 showed that Li Ge, Liu Xiaozhong, and Zhang Chaohui and their respective concert parties had each disclosed approximately 8.70% interests; New WuXi Life Science Holdings Limited held approximately 8.49%; and BlackRock disclosed a long position of approximately 5.60% and a short position of approximately 0.11%. Investing.com’s institutional ownership summary showed mutual funds and ETFs holding approximately 32.66% of the free float, other institutional investors approximately 14.93%, and public companies and retail investors approximately 52.41%. These shareholder and institutional-holding data have different reporting dates and quarterly lags and should not be treated as the real-time ownership structure on September 11, 2026. The structure may have changed subsequently. Existing data indicate that the company is not held entirely by the controlling-shareholder family or management. Large institutions such as BlackRock, as well as funds and ETFs, participate, while public and retail ownership remains substantial. WuXi Biologics is not a low-liquidity small-cap stock, and buying and selling orders are generally sufficient under normal conditions. However, if turnover expands near a support zone while the share price still closes at a low level, this may indicate intensified exchange of seller inventory and should not simply be interpreted as bargain hunting.

A volume-confirmation signal that can be monitored is as follows: if daily turnover reaches approximately HK$1.8 billion or more in the coming week and the share price simultaneously recovers HK$49.0 to HK$49.5, the rebound may be regarded as volume-supported. If turnover expands while the share price breaks below HK$46.1, the signal would be closer to high-volume distribution or stop-loss pressure.

④ Key Points to Monitor (Observation Framework Only, Not Trading Instructions)

• Observe whether HK$46.1 to HK$46.4 holds, as this is the first short-term dividing line between bulls and bears. If decisively breached, observe the HK$44.4 to HK$45.0 strong-support zone. This is an observation framework, not an instruction to buy, sell, or hold.
• Observe whether HK$49.0 to HK$49.5 can be regained and held. This range is close to the MA10, MA20, and Bollinger mid-band. The HK$50.5 to HK$51.4 resistance zone should then be monitored. This is an observation framework, not an instruction to buy, sell, or hold.
• Observe whether daily turnover can exceed approximately HK$1.8 billion and whether it is consistent with the direction of the price breakout. A volume-supported rise recovering HK$49.0 to HK$49.5 has a different technical implication from a volume-supported decline below HK$46.1. This is an observation framework, not an instruction to buy, sell, or hold.
• Monitor whether the short-selling share of turnover remains high and whether the healthcare sector and Hang Seng Index experience a simultaneous one-way move. This is an observation framework, not an instruction to buy, sell, or hold.

The above scenario analysis is based on closing data as of September 11, 2026, as well as historical prices and technical-indicator calculations. Short-term share prices will also be affected by news flow, capital flows, the broader market environment, and other factors. Technical indicators are inherently lagging and limited. This does not guarantee actual future performance or constitute a buying or selling recommendation. Investors should make independent judgments based on the latest market information and bear their own investment risks.

6. Industry Landscape and Competitor Analysis

6.1 Industry Overview

The global biologics CRDMO industry provides biopharmaceutical companies with outsourced services spanning drug discovery, development, clinical manufacturing, and commercial manufacturing. Core competitive factors include regulatory and quality systems, complex-biologics capabilities, global capacity, end-to-end services, customer switching costs, and multi-region supply capabilities. The overall industry remains relatively fragmented, but the concentration and competitive advantages of large integrated platforms are increasing.

6.2 Competitive Landscape

• High regulatory and quality barriers: Biologics manufacturing involves cell culture, purification, viral clearance, aseptic filling, and batch-consistency controls. Switching suppliers generally requires renewed technology transfer, process validation, and regulatory communications.
• High capital-expenditure and capacity-scale requirements: Large biologics facilities require substantial capital investment. New facilities must also undergo validation, customer onboarding, and capacity ramp-up. Large-scale production and standardized processes help create cost and delivery advantages.
• Service models are shifting from single-process manufacturing outsourcing toward end-to-end CRDMO: Customers tend to seek integrated providers that can cover drug discovery, development, clinical manufacturing, and commercial manufacturing.
• Rising importance of global dual sourcing: Large pharmaceutical companies need to reduce reliance on a single country, plant, or supplier. Companies with manufacturing capabilities across China, the US, Europe, and other parts of Asia are more likely to win global projects. However, global footprints also create regulatory, tariff, export-control, geopolitical, and regional cost-structure risks.
• Competition is not solely about capacity: Complex-molecule development, commercial quality systems, ADC and bispecific-antibody capabilities, global supply chains, customer financing, and project-management capabilities are also important.
• No unverified single third-party figure has been used for global market share. Different institutions may or may not include drug products, ADCs, cell and gene therapy, vaccines, and early-stage research services in their biologics CDMO statistics. Precise market rankings should therefore not be based on such figures.

6.3 Major Competitors

WuXi Biologics, Samsung Biologics, and Lonza all possess global manufacturing and commercial-service capabilities. WuXi Biologics’ differentiated strengths are more concentrated in early discovery, cell-line and process development, complex antibodies, end-to-end CRDMO, and project onboarding speed. Compared with Patheon and Catalent, the company is more focused on biologics research and manufacturing. Compared with GenScript ProBio, its project scale, commercial manufacturing depth, and integrated platform are more pronounced. The business structures of these comparable companies are not fully identical. Some are business platforms under larger groups or entities not listed in Hong Kong, so direct comparisons of market capitalization or margins are inappropriate.

7. Risk Factors

• Overseas business and geopolitical risk: North America and Europe together accounted for approximately 81.2% of 2025 revenue, indicating significant dependence on overseas customers and markets. Changes in global regulation, tariffs, export controls, data compliance, and regional supply-chain policies could affect order acquisition, project delivery, capacity allocation, or revenue recognition.
• Backlog-conversion risk: Total backlog at the end of 2025 was approximately US$23.0 billion, including potential milestone payments of approximately US$12.2 billion, while approximately US$4.5 billion is expected to be recognized over the next three years. Conversion of potential milestones on schedule depends on customer project progress, clinical outcomes, regulatory approvals, commercialization arrangements, and contractual terms. It should not be equated with contracted revenue.
• Customer-credit and receivables risk: Net trade receivables at the end of 2025 were RMB 7.647 billion, overdue receivables were approximately RMB 2.561 billion, and receivables overdue for more than 90 days were approximately RMB 1.094 billion. Relevant long-overdue balances are unsecured. If customers experience financing difficulties or projects are delayed or fail, collections could be delayed and impairment or contract-asset risks could arise.
• Capacity-utilization and margin risk: New facilities in Ireland, Germany, the US, and other locations must undergo validation, customer onboarding, and capacity ramp-up. If project onboarding or commercial manufacturing growth falls short of expectations, depreciation, labor, and manufacturing overhead could again dilute gross margin and weaken the sustainability of the adjusted gross-margin improvement seen in the first half of 2026.
• Supply-chain and cost risk: The top five suppliers accounted for approximately 36% of total purchases in 2025 and the largest single supplier for approximately 15%. The company does not possess complete pricing power over single-use consumables, filtration consumables, specialty resins, laboratory equipment, and certain high-end bioprocess materials. Supply disruptions, delivery delays, or higher procurement costs could affect project schedules and gross margin.
• Foreign-exchange and reported-profit volatility: The depreciation of the US dollar in the first half of 2026 caused unrealized foreign-exchange losses, resulting in only 4.3% growth in IFRS net profit attributable to owners, significantly below the 38.4% growth in adjusted net profit attributable to owners. The company’s orders and some businesses are denominated or settled in US dollars, and currency movements may continue to cause divergences between reported profit and core operating performance.
• Valuation downside risk: As of September 11, 2026, the share price was HK$46.64, with a forward P/E of approximately 33x to 35x and a P/B ratio of approximately 3.6x to 3.8x. Valuation already reflects part of the expected growth and margin improvement. If revenue growth, overseas orders, commercial-project conversion, or gross margin fall below market expectations, valuation compression may occur.
• Short-term price and trading-structure risk: The share price was below the MA5, MA10, and MA20 and close to the HK$46.1 to HK$46.4 support zone. A volume-supported break below this range could lead to a retracement toward HK$44.4 to HK$45.0. The short-selling share of turnover was high on some September trading days, but short-selling data cannot be directly equated with selling by major shareholders or net capital outflows. Price direction may still be affected by market sentiment and trading structure.
• Share-capital change risk: At least approximately 8.3289 million new shares were issued through existing option exercises from early September through September 9, 2026, bringing issued shares to approximately 4.156 billion. Although current dilution is small, further option exercises could increase the number of shares and create some dilution to EPS.

8. Conclusion and Outlook

The company’s growth drivers primarily comprise expansion in project numbers, continued onboarding of early-stage projects and their conversion into late-stage clinical and commercial projects, and development of complex-molecule businesses such as bispecific antibodies, multispecific antibodies, and XDC. The 123 organically added integrated projects in the first half of 2026 increased 43% year on year. Together with new commercial manufacturing projects and the existing backlog, this should support future revenue growth. The non-exclusive technology license granted by Transcenta for HiCB and ExcelPro also provides an opportunity to expand platform capabilities, although public information does not disclose the number of cooperation projects, future milestone amounts, or revenue contribution.

Profitability has shown signs of improvement. Adjusted gross margin was 48.4% in the first half of 2026, while adjusted EBITDA was approximately RMB 5.4 billion, up 24.9% year on year. Whether margins can continue to improve will depend on the ramp-up of new overseas facilities, capacity utilization, the share of commercial projects, growth in complex-molecule businesses, and the effectiveness of WBS and digital cost reductions. Market forecasts imply continued revenue and profit growth from 2026 to 2028, but current valuation already reflects part of the expected revenue recovery, margin improvement, and complex-molecule growth. The extent to which earnings are delivered and valuation is absorbed will therefore be critical.

From a short-term trading perspective, the share price remains below the main short-term moving averages, while short-selling turnover accounted for approximately 14.6% to 18.1% of turnover from September 9 to 11, indicating some hedging and selling pressure. If HK$46.1 to HK$46.4 breaks, the technical structure could weaken. If the price regains HK$49.0 to HK$49.5 with volume support, there would be signs of improvement in the short-term weak structure. These price ranges reflect scenario observations based on currently available data only and do not constitute investment advice.

Data Sources

• https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0429/2026042900764.pdf
• WuXi Biologics Reports Record 2025 Annual Results
• Poised for Accelerated Growth
• Financial Highlights
• Samsung Biologics introduces optimized manufacturing framework, ExellenS™ | Samsung Biologics
• Lonza | Integrated Biologics
• End-to-end Pharma Services Solutions for Every Drug Development Journey
• Our Business
• WuXi Biologics Reports Strong Profitable Growth in H1 2026
• WuXi Biologics Reports Record 2025 Annual Results
• 02269 WUXI BIO - Free Real-Time Stock Quote - Earnings Forecast - etnet Hong Kong News, Financial Information and Lifestyle Platform
• WuXi Biologics (Cayman) Inc.: Company Events Publications and Financial Calendar | 1FW2 | KYG970081173 | MarketScreener Hong Kong
• WuXi Biologics (Cayman) Inc.: Financial Data Forecasts Estimates and Expectations | WXXWY | US98260N1081 | MarketScreener
• CICC Says WuXi Biologics’ (02269.HK) Profitability Improved; Raises Target Price 25% to HK$60 and Increases Earnings Forecasts
• Citi Raises WuXi Biologics (02269.HK) Target Price from HK$42 to HK$62, Rating “Buy”
• WuXi Biologics (02269.HK): Innovation-Driven Business Developing Rapidly; Bispecific and Multispecific Antibodies May Become Core Future Growth Engines
• FIRST SHANGHAI GROUP - E-commerce
• 02269.HK WuXi Biologics | WUXI BIO | Company Information - Basic Data Overview - etnet
• Listed Company Information Title Search
• irasia.com - Returns on Share Capital of Listed Companies in Asia
• WuXi Biologics (02269) Issues 3.2 Million Shares Upon Exercise of Options
• Hong Kong Stock Exchange Disclosure
• 2269.HK Announcements | Real-Time Quote | Hong Kong Real-Time Stock Market Depth Analysis and Expert Views - etnet
• Analysis of Stock Connect Holdings in Hong Kong Stocks | September 8
• 02269 WUXI BIO - Stock Short Selling - etnet
• WuXi Biologics’ Interim Revenue Reaches RMB 11.787 Billion; Adjusted Net Profit Up 38.4%
• Transcenta Therapeutics and WuXi Biologics Enter into Strategic Collaboration to Accelerate Commercialization of HiCB Continuous Bioprocessing Technologies-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
• 2269.HK WUXI BIO - Company Information - WUXI BIO Background - etnet
• Equity Research - Company Information - Quote Data - AASTOCKS.com
• WuXi Biologics (02269) Price-to-Sales Ratio | Valuation | Fundamentals - Lixinger
• WuXi Biologics (2269) Historical Prices - Investing.com
• Hong Kong Exchanges and Clearing Limited

This report was automatically researched, compiled, and generated by AI based on publicly available information. The information is as of the Hong Kong market close on September 11, 2026; the exact trading dates corresponding to the 52-week high and low have not been verified. Information may differ in timeliness. Specific data should be based on the company’s official announcements and authoritative data terminals. This report is for information organization and research reference only and does not constitute investment advice. Investors should make independent judgments and bear their own investment risks.